Twist acquires iGenomX for $35M

By Melissa Busch, The Science Advisory Board contributing writer

June 30, 2021 -- Twist Bioscience has acquired next-generation sequencing library preparation developer iGenomX for $35 million. The deal gives Twist a leg up in the shift from genotyping with static microarray platforms to using sequencing workflows.

IGenomX's sequencing library maximizes lab capacity for numerous applications, including the microbiome, synthetic biology, agrigenomics, and population genetics. The acquisition expands Twist's next-generation sequencing capabilities into new markets, while also accelerating the conversion to genotyping by sequencing workflows.

The total purchase consideration was $35 million, including a $500,000 cash payment and $29.5 million in Twist stock. Additionally, it included a contingency payment of $5 million in Twist shares upon completion of meeting specific milestones.

Twist, Regeneron partner on genetics NGS panel
Twist Bioscience is collaborating with Regeneron subsidiary Regeneron Genetics Center to launch a custom next-generation sequencing (NGS) population genetics...
Twist launches enzymatic fragmentation library prep kit
Twist Bioscience has unveiled its Twist Library Preparation Enzymatic Fragmentation Kit 2.0, an all-in-one solution designed to maximize accuracy and...
Twist announces Q2 financial results
Twist Bioscience announced that revenues grew in the company's second quarter of fiscal 2021, although the firm's net loss also grew.
Twist, Vivlion to generate gRNA libraries for CRISPR applications
Twist Bioscience and Vivlion are collaborating to generate guide RNA (gRNA) libraries for CRISPR genome engineering applications and target discovery...
Pure Biologics, Twist partner on immuno-oncology drugs
Pure Biologics and Twist Bioscience have partnered to accelerate the discovery of antibody-based immuno-oncology drugs.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter